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From the Editor’s Desk
INCREASED MEDICAL 
SCHOOL PLACES: 
A CRISIS IN THE MAKING?
This year, some 2400 young Australians 
entered our medical schools, and in the 
coming years their numbers will increase 
further. The Prime Minister recently 
announced yet another new medical school 
and continues to top up medical school 
places.
With these developments one thing is 
obvious — policy announcement is easy, but 
policy implementation is not. Already, there 
is talk that the existing health system might 
find it difficult to meet the educational needs 
of increased numbers of students. Already, 
medical students are voicing concern about 
the effect of increased student numbers on 
the quality of their education in the clinical 
years, especially the high student-to-teacher 
ratios and projected bottlenecks in future 
vocational training. And this pressure-
cooker environment can only worsen. 
In short, we are heading to a crisis in medical 
education.
There is talk in academic circles of 
“new ways” — sharing teaching hospitals 
among medical schools, simulation centres, 
increased involvement of private hospitals, 
specialist and general practices, and 
community health services in teaching. 
But the realisation of these new ways 
requires time, as does the development 
of skilled clinical teachers.
Undoubtedly, the issue is complex. 
Crucial to effective medical education is 
the capacity of an already stretched public 
hospital system to sustain both service 
delivery and quality clinical training.
It’s time for the federal and state 
governments to take stock and ensure 
that medical education and training 
are not jeopardised by overburdened, 
under-resourced and suboptimal clinical 
environments. Funding for capacity building 
is necessary, but undoubtedly will fall victim 
to the federal–state political game of who 
pays. No matter that both are responsible for 
the health rights of all Australians.
The last thing we want is a future 
generation of medical students disillusioned 
through questionable quality of clinical 
exposure and experience.
Martin B Van Der Weyden
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Letters
Systemic allergy to 
topical hexamidine
Raymond J Mullins
TO THE EDITOR: Food, medication or
insect stings are the major causes of systemic
allergic reactions.1 That topical agents can
mimic such reactions is not commonly
appreciated. I report here a systemic allergic
reaction to a topical medication (initially
attributed to food).
A 7-year-old boy experienced generalised
urticaria and facial swelling within an hour
of eating a peanut-containing slice. His
father recalled applying a topical antiseptic
(Medi Creme [Pharmacare]) to a graze over
the boy’s right elbow at about the same time.
There were no respiratory or cardiovascular
symptoms, and the urticaria settled within 2
hours of taking oral promethazine.
Six months later, the same cream applied
to a graze over the boy’s right chest resulted
in a localised 15 cm urticarial welt. Intercur-
rent problems included atopic dermatitis
but no known food or drug hypersensitivity.
The active ingredients of Medi Creme are
hexamidine isethionate, chlorhexidine ace-
tate, cetrimide and lignocaine hydro-
chloride. With the assistance of the
manufacturer, skin prick tests using a 10%
weight/volume suspension of Medi Creme
or a 10% suspension of hexamidine
isethionate in normal saline produced 5 mm
itchy weals at 15 minutes in the patient (but
not controls). By contrast, skin prick tests to
the other active ingredients, inert vehicles
and relevant foods (including peanut,
almond, brazil nut, cashew, hazelnut, pecan,
walnut, sunflower seed and sesame seed)
were negative. Avoidance of hexamidine was
advised. The child has eaten peanut prod-
ucts before and since without any adverse
reaction.
Hexamidine is an aromatic diamidine
antiseptic (other members of the group
include pentamidine and dibrompropami-
dine). These drugs have broad antibacterial
and antifungal properties and are also used
topically to treat corneal infections and
some skin infections.2 In Australia, hexami-
dine is an ingredient of one topical local
anaesthetic/antiseptic cream (Medi Creme)
and one nappy rash cream, as well as some
tinea treatment creams, medicated sham-
poos, sunscreens and cosmetic facial wipes
in other countries. Adverse reactions (such
as contact  al le rgic  dermati t i s  and
photodermatitis3) are rare — only four
reports of localised dermatitis have been
reported to Australia’s Adverse Drug Reac-
tions Advisory Committee (ADRAC) in the
past 6 years (Dr K Mackay, Acting Director,
ADRAC, Adverse Drug Reactions Unit,
Therapeutic Goods Administration, per-
sonal communication). There have been
more reports of systemic allergic reactions
(including anaphylaxis) triggered by chlor-
hexidine or cetrimide,4 with one description
of anaphylaxis to hexamidine after patch
testing, but none with clinical use.3 Under-
lying dermatitis is a risk factor for sensitisa-
tion to topical agents.5
This case emphasises the importance of
documenting exposure to potential aller-
genic triggers in the setting of a short-lived
episode of urticaria (where the search for an
avoidable trigger is more likely to be pro-
ductive) or anaphylaxis. Exposure to sting-
ing insects is usually obvious, whereas
exposure to particular foods or medications
is often poorly recalled. That topical aller-
gens can also trigger systemic reactions
should be considered.
Raymond J Mullins, PhD, FRACP, FRCPA, 
Clinical Immunologist
John James Medical Centre, Canberra, ACT.
rmullins@allergycapital.com.au
1 Golden DB. Patterns of anaphylaxis: acute and late
phase features of allergic reactions. Novartis Found
Symp 2004; 257: 101-110; discussion 110-115, 157-
160, 276-285.
2 Perrine D, Chenu JP, Georges P, et al. Amoebicidal
efficiencies of various diamidines against two
strains of Acanthamoeba polyphaga. Antimicrob
Agents Chemother 1995; 39: 339-342.
3 Revuz J, Poli F, Wechsler J, Dubertret L. [Contact
dermatitis from hexamidine] [French]. Ann Derma-
tol Venereol 1984; 111: 805-810.
4 Krautheim AB, Jermann TH, Bircher AJ. Chlorhexi-
dine anaphylaxis: case report and review of the
literature. Contact Dermatitis 2004; 50: 113-116.
5 Guillet G, Guillet MH, Dagregorio G. Allergic con-
tact dermatitis from natural rubber latex in atopic
dermatitis and the risk of later Type I allergy. Con-
tact Dermatitis 2005; 53: 46-51. ❏
Microbial keratitis associated 
with overnight wear of silicone 
hydrogel contact lenses
John A Landers and John L Crompton
TO THE EDITOR: Extended-wear silicone
hydrogel contact lenses allow the conven-
ience of 24-hour correction of refractive
error and freedom from cleaning solutions
and storage containers. However, they are
associated with an increase in the risk of
microbial keratitis when worn overnight
compared with daily wear.1-5
The following cases from a single ophthal-
mology practice illustrate the risk to contact
lens wearers when they use silicone hydro-
gel contact lenses overnight.
A 36-year-old woman presented 11 days
after sleeping with her silicone hydrogel
contact lenses in overnight. She had increas-
ing right ocular pain and photophobia over
the preceding 9 days, which had not
resolved with chloramphenicol drops. On
examination, visual acuity was 6/18 right
and 6/6 left. Corneal cultures grew Acan-
thamoeba, which responded to polyhexa-
methylene biguanide and brolene drops
hourly. Her final best corrected visual acuity
was 6/9 right, 5 weeks later.
A 24-year-old woman presented with 2
days of left ocular pain, conjunctival injec-
tion, and epiphora following continuous
silicone hydrogel contact lens use over the
preceding week. On examination, visual
acuity was 6/6 right and 6/18 left. A central
corneal ulcer with stromal infiltrate and
significant anterior chamber activity was
present in her left eye (Box). Corneal cul-
tures grew Pseudomonas aeruginosa, which
responded to topical gentamicin 1% drops
hourly. Her final best corrected visual acuity
was 6/5 left, 3 weeks after diagnosis.
An 8-year-old girl was seen 2 months after
commencing continuous wear of her sili-
cone hydrogel contact lenses for uniocular
myopia. She had worn the same lenses for 4
weeks continuously when she presented
with a 2-day history of right ocular irrita-
tion, photophobia, and conjunctival injec-
tion. On examination, visual acuity was 6/36
right and 6/6 left. She was commenced
empirically on cephalothin 5% and gen-
tamicin 1% drops hourly. Corneal cultures
did not grow any causative organism, and
her clinical condition improved significantly
over the following 7 days. Her final best
corrected visual acuity was 6/9 right.
Although microbial keratitis may only
affect a small proportion of individuals1,2,5
Microbial keratitis in a 24-year-old 
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cant reduction in vision following treatment,
microbial keratitis is potentially blinding
and should not be trivialised.
Silicone hydrogel contact lenses have a
lower risk of associated microbial keratitis
than other lens types, but they do not
remove it completely. In view of this, contact
lenses should not be worn overnight or for
an extended period. Furthermore, a painful
red eye in a contact lens wearer should be
considered microbial keratitis until proven
otherwise, and needs a prompt ophthalmol-
ogist referral.
John A Landers, Ophthalmology Registrar
John L Crompton, Ophthalmologist
Royal Adelaide Hospital, Adelaide, SA.
john.landers@bigpond.com
1 Stapleton F, Edwards K, Keay L, et al. The incidence
of contact lens related microbial keratitis in Aus-
tralia [abstract]. Invest Ophthalmol Vis Sci 2005; 46:
B228. Abstract No. 5025.
2 Morgan PB, Efron N, Hill EA, et al. Incidence of
keratitis of varying severity among contact lens
wearers. Br J Ophthalmol 2005; 89: 430-436.
3 Holden BA, Sankaridurg PR, Sweeney DF, et al.
Microbial keratitis in prospective studies of
extended wear with disposable hydrogel contact
lenses. Cornea 2005; 24: 156-161.
4 Lam DS, Houang E, Fan DS, et al; Hong Kong
Microbial Keratitis Study Group. Incidence and risk
factors for microbial keratitis in Hong Kong: com-
parison with Europe and North America. Eye 2002;
16: 608-618.
5 Schein OD, McNally JJ, Katz J, et al. The incidence
of microbial keratitis among wearers of a 30-day
silicone hydrogel extended-wear contact lens.
Ophthalmology 2005; 112: 2172-2179. ❏
TB or not TB: treat to see
Paul L A van Daele, Marleen Bakker, 
P Martin van Hagen, G Seerp Baarsma 
and Robert W A M Kuijpers
TO THE EDITOR: Uveitis is an intraocular
inflammation which potentially leads to per-
manent loss of vision.1,2 Tuberculosis is con-
sidered to be an infrequent infectious cause
of uveitis in the developed world. However,
its recurrence as a major public health prob-
lem raises the possibility that the incidence
of tuberculosis-related uveitis in the devel-
oped world may rise.3,4 Uveitis in tuberculo-
sis is presumed to result from either direct
invasion or a hypersensitivity reaction.
At the ophthalmology departments of the
Erasmus Medical Center and the Eye Hos-
pital in Rotterdam, The Netherlands, all
patients presenting with refractory uveitis
undergo investigation for a systemic cause,
including tuberculin skin testing. When
ocular findings are consistent with intraocu-
lar tuberculosis, and the tuberculin skin test
is positive, while no other cause of uveitis is
suggested by symptoms, signs or ancillary
testing, then a diagnosis of presumed
intraocular tuberculosis is made. Using
these criteria, eight cases of presumed
intraocular tuberculosis were identified
among 89 people referred with refractory
uveitis between January 2002 and January
2004. Characteristics of the eight patients
are shown in the Box. One patient (F)
withdrew from clinical care, and another (A)
later had a positive culture result for tuber-
culosis on lymph node biopsy. This patient
had complete remission of uveitis after
tuberculostatic treatment, but was excluded
from this study as the aim was to assess
whether antituberculosis treatment is war-
ranted based solely on a positive tuberculin
skin test.
We treated the patients with a complete
tuberculostatic regimen (2 months of isoni-
azid, rifampicin, ethambutol and pyrazina-
mide, followed by 4 months of isoniazid,
rifampicin and ethambutol). All had been
previously treated for more than 3 years
with immunosuppressive drugs (mainly cor-
ticosteroids), either local or systemic, or
both, without adequate response.
Main outcome measures were visual acu-
ity and degree of intraocular inflammation
seen on ophthalmological examination
before and on completion of antituberculo-
sis therapy.
The predominant clinical finding was
blurred vision. Five patients exhibited
decreased intraocular inflammation and an
increase in visual acuity after antituberculo-
sis treatment, allowing tapering of the corti-
costeroid treatment. One patient had no
response. Improvement as part of the natu-
ral history was regarded unlikely.
As our department is a tertiary referral
centre for patients with uveitis, our patient
population is not a representative sample of
all patients with uveitis in The Netherlands.
Nevertheless, our findings suggest that
Details of eight patients with presumed intraocular tuberculosis
Affected 
eye Place of birth
Visual acuity
Uveitis 
treatment
Antituberculosis 
treatmentPatient Sex Age Uveitis Before* After* Response
A M 25 Left Anterior Congo NR† NR† NR† NR† NR†
B F 40 Both Posterior Cape Verde 1.8/6 (R), 
1.2/6 (L)
4.8/6 
(both)
Local 
steroids
HRZE, 
HRE
Partial response, 
local steroids continued
C F 69 Left Posterior Netherlands‡ 4.8/6 4.8/6 Local 
steroids
HRZE, 
HRE
Complete response, 
local steroids stopped
D M 49 Right Posterior Surinam 0.6/6 0.8/6 Vitrectomy, 
local steroids
HRZE, 
HRE
No response
E F 36 Both Anterior Morocco 2.4/6 (R), 
3/6 (L)
4.8/6 (R), 
6/6 (L)
Local 
steroids
HRZE, 
HRE
Complete response, 
local steroids stopped
F F 62 Both Posterior Morocco 0.6/6 (R), 
0.6/6 (L)
Local 
steroids
— Lost to follow up 
before treatment
G M 54 Right Posterior Surinam 2.4/6 5.5/6 Local and 
systemic steroids
HRZE, 
HRE
Partial response, 
systemic steroids stopped
H F 19 Both Intermediate Netherlands‡ 4.3/6 (R), 
1.2/6 (L)
6/6 (R), 
6/6 (L)
Local steroids HRZE, 
HRE
Complete response, 
local steroids stopped
* Before and after antituberculosis therapy. † NR = no result as patient excluded from the study. ‡ Patient C’s parents were born in The Netherlands, but Patient H’s 
parents were from Morocco. M = male. F = female. H = isoniazid. R = rifampicin. Z = pyrazinamide. E = ethambutol. ◆178 MJA • Volume 185 Number 3 • 7 August 2006
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ered in the differential diagnois of uveitis,
even in developed countries.
We believe that, given our results, antitu-
berculosis therapy is justified in patients with
uveitis even when a positive tuberculin skin
test is the only argument for tuberculosis as
the cause of the eye disease. An additional
argument for antituberculosis treatment is
that many patients with uveitis refractory to
immunosuppressive therapy can be ade-
quately treated with tumour necrosis factor-α
(TNF-α)  blocking drugs.5 However, as severe
tuberculosis infection has been described
after use of these agents, antituberculosis
therapy is warranted in any patient with a
positive tuberculin skin test who is a candi-
date for TNF-α blocking therapy.
Paul L A van Daele, Internist1
Marleen Bakker, Pulmonologist1
P Martin van Hagen, Internist1
G Seerp Baarsma, Ophthalmologist2
Robert W A M Kuijpers, Ophthalmologist1
1 Erasmus Medical Center, Rotterdam, 
The Netherlands.
2 The Eye Hospital, Rotterdam, 
The Netherlands.
p.l.a.vandaele@erasmusmc.nl
1 Durrani OM, Meads CA, Murray PI. Uveitis: a poten-
tially blinding disease. Ophthalmologica 2004; 218:
223-236.
2 Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis
and systemic disease. Br J Ophthalmol 1992; 76:
137-141.
3 Morimura Y, Okada AA, Kawahara S, et al. Tubercu-
lin skin testing in uveitis patients and treatment of
presumed intraocular tuberculosis in Japan. Oph-
thalmology 2002; 109: 851-857.
4 Sheu SJ, Shyu JS, Chen LM, et al. Ocular manifesta-
tions of tuberculosis. Ophthalmology 2001; 108:
1580-1585.
5 Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen
PM. Anti-TNF-alpha therapy for sight threatening
uveitis. Br J Ophthalmol 2005; 89: 533-536. ❏
Mycobacterium ulcerans 
infection: a rediscovered focus 
in the Capricorn Coast region 
of central Queensland
Glenn Francis, Michael Whitby and 
Marion Woods
TO THE EDITOR: Mycobacterium ulcerans
is an environmental pathogen with a global
geographic distribution and focal disease
clusters. The World Health Organization
considers M. ulcerans infection to be of
increasing global importance, particularly in
West Africa.
In Australia, the clinical and pathological
features were fully described in 1948, when
the disease was named Bairnsdale ulcer.1
Since then, the number of cases has increased,
and new focal areas continue to emerge
around southern coastal Victoria.2 In Queens-
land, the disease is most frequently reported
in the Mossman area (north of Cairns in north
Queensland), where it is known as Daintree
ulcer.3 However, the organism is probably
more widely distributed.
We describe four patients recently diag-
nosed with proven M. ulcerans infection in
the Capricorn coast region of central
Queensland (Box). The suspected epicentre
of infection is around Yeppoon, approxi-
mately 1000 km south of Mossman.
None of the patients had significant con-
tact with recognised endemic areas in north
Queensland or Victoria. Patient 1 had vis-
ited Townsville in July 2000, but had mini-
mal contact with the natural environment.
She undertook extensive gardening at her
home in North Rockhampton, using sugar
cane bagasse mulch from north Queensland.
The previous occupants of her house had
lived in north Queensland and left behind at
her home numerous potted plants originally
from that area. However, investigation of
soil from potted plants, gardens and roses at
the home using polymerase chain reaction
(PCR) failed to detect any evidence of M.
ulcerans.
Patient 2 lived near a coffee plantation
originally planted with seeds transported
from north Queensland. Sampling of plants
and soil in the area by PCR revealed no
atypical mycobacteria.
M. ulcerans is an environmental organism
associated with bodies of water, but its spe-
cific ecological niche is unknown.4 The
organism is difficult to culture from the envi-
ronment but has been identified by PCR in
water, biofilms, aquatic insects, snails and
fish. The mode of transmission to humans
remains unknown. It has shown a marked
propensity for causing intense focal out-
breaks in Victoria (Phillip Island and Point
Lonsdale) and Queensland (Daintree region).
The recognition that M. ulcerans occurs in
coastal central Queensland is important, as
early diagnosis of M. ulcerans infection mini-
mises the extent of tissue debridement nec-
essary and improves outcomes. The patients
we describe had complicated disease requir-
ing multiple debridements and, in one case,
amputation. Awareness of the possibility of
M. ulcerans infection is critical, as diagnosis
by PCR is straightforward once the infection
is considered in the differential diagnosis.
In 1942, Cilento described possible M.
ulcerans infections from around Rockhamp-
ton.5 Four other culture-confirmed cases
were reported between 1957 and 1962 from
the Glass House Mountains (Sunshine
Coast)3 and Maryborough (Fraser Coast)6-8
regions in Queensland. Our four cases
Four patients with Mycobacterium ulcerans infection in central Queensland
Age/sex Location Presentation Site 
Clinical 
features Diagnosis Treatment
47 F North 
Rockhampton
Sep 2000 Fifth 
finger 
(left hand)
Nodule Histology,
PCR
Debridement, 
antimycobacterial 
antibiotics, 
amputation
33 F Yeppoon Jun 2003 Left knee Ulcer Histology,
culture
Debridement
64 M Bungundarra Aug 2004 Right 
elbow
Ulcer Histology,
PCR
Multiple 
debridements
18 M Keppel Sands Nov 2004 Right 
knee
Ulcer Histology, 
culture
Multiple 
debridements,
antimycobacterial 
antibiotics
PCR = polymerase chain reaction. F= female. M = male. ◆MJA • Volume 185 Number 3 • 7 August 2006 179
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centred on Yeppoon and the suburbs of
Rockhampton. If the cases previously
described by Cilento were truly related to M.
ulcerans, then there appears to have been a
five-decade gap in identification of M. ulcer-
ans infection in the Capricorn Coast region
of central Queensland. Possible explana-
tions for this include low organism numbers
resulting in sporadic infection, focal concen-
trations of the organism with environmental
changes, such as development, land clearing
and cultivation modifying human contact,
or failure to diagnose the condition. Patients
who acquired the infection in central
Queensland may also have been diagnosed
outside the area.
The increase in cases in Victoria raises the
possibility of a potentially similar dramatic
increase in cases in central Queensland.
Consideration should be given to making M.
ulcerans infection a reportable disease to
enable monitoring.
Glenn D Francis, Director, Department of 
Pathology1
Michael Whitby, Director, Infection 
Management Services1
Marion Woods, Infectious Diseases Physician2
1 Princess Alexandra Hospital, Brisbane, QLD.
2 Royal Brisbane Hospital, Brisbane, QLD.
glenn_francis@health.qld.gov.au
1 Macullum P, Tolhurst JC, Buckle G, Sissions HA. A
new mycobacterial infection in man. J Pathol Bac-
teriol 1948; 60: 93-122.
2 Johnson PD, Veitch MG, Leslie DE, et al. The
emergence of Mycobacterium ulcerans infection
near Melbourne. Med J Aust 1996; 164: 76-78.
3 Radford AJ. Mycobacterium ulcerans in Australia.
Aust N Z J Med 1975; 5: 162-169.
4 Roberts B, Hirst R. Immunomagnetic separation
and PCR for detection of Mycobacterium ulcerans.
J Clin Microbiol 1997; 35: 2709-2711.
5 Cilento R. Leprosy (elephantiasis graecorum). In:
Tropical diseases in Australasia. Brisbane: WR Smith
and Paterson, 1944: 306.
6 Annual report of the health and medical services of
the State of Queensland for the year 1957-58.
Brisbane: SG Reid, Government Printer, 1958: 95.
7 Annual report of the health and medical services of
the State of Queensland for the year 1958-59.
Brisbane: SG Reid, Government Printer, 1959: 95-97.
8 Lane D. Mycobacterium ulcerans infection in
Queensland. Med J Aust 1964; 1: 124-125. ❏
Clinical outcomes associated 
with changes in a chronic 
disease treatment program 
in an Australian Aboriginal 
community
Ross S Bailie
TO THE EDITOR:
• “… what a difference can be made and
how bureaucracies can stuff things up”.
• “… systematic testing and treatment of
people with high blood pressure and kidney
disease dramatically improved blood pres-
sure and resulted in a 50% reduction of
deaths”.
• “… excellent results were achieved by
good management and they were lost when
intensity of management was relaxed”.
The above quotes are from an episode of
The health report broadcast late last year on
Radio National.1 The episode, which
described a deterioration in the health of an
Indigenous community after a chronic dis-
ease treatment program was handed over to
a community health board, caused me to
take a closer look at the articles in the
Journal by Hoy and colleagues on which the
claims were based.2,3 I found several issues
of concern.
The small numbers of deaths each year
in the study community and the analysis
and presentation of the death data mean
that the conclusions about trends in mor-
tality over time are tenuous. This is high-
lighted by the discrepancies between the
two articles in the terminology used to
classify deaths, in the numbers of deaths
reported, and in the trends over time.
Discrepancies in terminology or numbers
of reported deaths are not explained. The
declining trend in the number of “natural”
deaths described in the 2000 article is not
apparent in the “non-renal” deaths in the
2005 article. The rate of “non-renal” death
for the period 1996–97 to 1998–99
reported in the 2005 article appears to be
increasing rather than declining, as
described in the 2000 article (rates for
earlier years are not presented in either
article). It is clear that, with these small
numbers, the reclassification or misclassifi-
cation of a single death can affect the trends
in “renal death” or end-stage renal disease
over time, and that the use of “rolling
averages” hides the year-to-year variability
that would be expected in these data.
The trend over time in the key intermedi-
ate outcome indicator of blood pressure
control does not support the conclusion
regarding impact of the “handover” on the
program. The data presented in the 2005
article show a decline in control commenc-
ing in the third year. An earlier analysis of
the same data showed the decline in blood
pressure control began as early as the second
year after entry into the program.4 Neither
analysis shows any clear change in the
declining trend in blood pressure control
around the time of “handover” of the pro-
gram.
While the discussion of the findings of the
2005 article is circumspect, at the time of
interview, Hoy conspicuously did not deny
the statement of The health report host that
the primary cause of the apparent loss of the
early impact of the program was the
bureaucracy “stuffing up”. The article makes
some important points about the operation
of chronic disease programs, but makes no
mention of the commonly experienced diffi-
culties of sustaining health programs,5,6 or
the research requirements for understanding
sustainability.7
These issues raise serious questions about
the validity of the conclusions and the sim-
plistic claims arising from the articles.
Ross S Bailie, MD, FAFPHM, Professor of Public 
Health
Menzies School of Health Research, Charles 
Darwin University, Tiwi, NT.
ross.bailie@menzies.edu.au
1 Aboriginal health [transcript of radio program]. The
health report. ABC Radio National broadcast, 08:30;
7 Nov 2005. Available at: http://www.abc.net.au/rn/
talks/8.30/helthrpt/stories/s1496205.htm (accessed
May 2006).
2 Hoy WE, Kondalsamy-Chennakesavan SN, Nicol JL.
Clinical outcomes associated with changes in a
chronic disease treatment program in an Australian
Aboriginal community. Med J Aust 2005; 183: 305-
309. 
3 Hoy WE, Baker PR, Kelly AM, Wang Z. Reducing
premature death and renal failure in Australian
Aboriginals. A community-based cardiovascular
and renal protective program. Med J Aust 2000;
172: 473-478. 
4 Robinson G, Bailie R, Wang Z, et al. A follow-up
study of outcomes of the Tiwi Renal Treatment
Program. Darwin: NTUniprint, Northern Territory
University, 2003.
5 Shediac-Rizkallah MC, Bone LR. Planning for the
sustainability of community-based health programs:
conceptual frameworks and future directions for
research, practice and policy. Health Educ Res 1998;
13: 87-108.
6 Bossert TJ. Can they get along without us? Sustain-
ability of donor-supported health projects in Cen-
tral America and Africa. Soc Sci Med 1990; 30: 1015-
1023.
7 Jackson N, Waters E, Anderson L, et al. Criteria for
the systematic review of health promotion and
public health interventions. Health Promot Int 2005;
20: 367-374. ❏180 MJA • Volume 185 Number 3 • 7 August 2006
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IN REPLY: I appreciate the feedback on the
2000 and 2005 articles describing the
dynamics and outcomes of the “Tiwi treat-
ment program”.1,2
Thorough and timely identification and
enumeration of deaths is a problem, espe-
cially for people not enrolled in the treat-
ment program. Without a register of such
people, systematic checking of their fate was
not possible. The additional “non-renal”
deaths in the community-at-large presented
in our 2005 article, compared with previous
articles, seem to have been captured largely
by the broad net spread by the Tiwi Health
Board when it assumed responsibility for its
primary care services, in an attempt to iden-
tify all its potential clients. This process
identified several hundred more people than
expected and captured additional deaths,
several dating back years. The precise defini-
tion of a community member is also a
problem, especially for people living perma-
nently or intermittently elsewhere (eg, in
Darwin or other communities).
The broadened definition of “renal
deaths” in the 2005 article,2 which accom-
modates people who died with renal failure
but did not begin dialysis, more fully repre-
sents the impact of renal disease. Con-
versely, recording only those who began
dialysis allows estimates of the impact on
health services and potential savings from
better management.3 Both approaches have
their place. Rolling averages, which indeed
have limits, were used in view of the overall
small and erratically spaced number of ter-
minal events in any year.
The figures we reported in our 2005
article did not show a deterioration in
blood pressure at Year 2, either in the
treatment group as a whole, or in the
smaller cohort followed for a full 6 years.2
An ear lier  analysis ,  which large ly
embraced the active years of the program,
also showed that blood pressure at Year 3
was not significantly different from that at
Year 2 (systolic blood pressure, P = 0.68)
(Box). With time, the number of people
who had moved through 3 years of treat-
ment increased, and the timing of their 3-
year blood pressure measurements moved
from a mix of 1998–1999 to 1999–2002,
when, as program dynamics suggest,
intensity of management was relaxed, and
mean values deteriorated, as we reported
in 2005.
The blood pressure measurements in the
report by Bailie’s group5 were compiled from
a review of paper-based medical records, the
clinic’s newly implemented Coordinated
Care Trial Information System, and the Ter-
ritory’s Information System (Systematic
Health Information Logically Organised), as
well our from our treatment program data-
base. Those blood pressures were allocated
time definitions in a different way, and the
summary data were derived from adjusted
predictions from cross-sectional time series
modelling, rather than from factual record-
ings at the stated intervals.5
I did not solicit the interview for The
health report, nor determine its directions
nor the resulting headlines. However, the
under-resourcing of primary care relative to
needs in remote Aboriginal settings, and
the lack of stability in the organisations in
which it is delivered, are very detrimental. I
regret that, once the Tiwi Health Board was
constituted, it was not mentored and sup-
ported through its difficulties. More
recently, the fledgling community-control-
led Gulf Health Service in the Borroloola
region of the Northern Territory met a
similar fate. Chronic disease remains
underserviced in both these regions, where
the people are among the sickest in Aus-
tralia.
Wendy E Hoy, Professor
Centre for Chronic Disease, Royal Brisbane 
Hospital, Brisbane, QLD.
w.hoy@uq.edu.au
1 Hoy WE, Baker PR, Kelly AM, Wang Z. Reducing
premature death and renal failure in Australian
Aboriginals. A community-based cardiovascular
and renal protective program. Med J Aust 2000;
172: 473-478. 
2 Hoy WE, Kondalsamy-Chennakesavan SN, Nicol JL.
Clinical outcomes associated with changes in a
chronic disease treatment program in an Australian
Aboriginal community. Med J Aust 2005; 183: 305-
309. 
3 Baker PRA, Hoy WE, Thomas RE. A cost and effects
analysis of a kidney and cardiovascular disease
treatment program in an Australian Aboriginal pop-
ulation. Adv Chronic Kidney Dis 2005; 12: 22-31.
4 Hoy WE, Wang Z, Baker PR, Kelly AM. Secondary
prevention of renal and cardiovascular disease:
results of a renal and cardiovascular treatment pro-
gram in an Australian aboriginal community. J Am
Soc Nephrol 2003; 14: S178-S185.
5 Robinson G, Bailie R, Wang Z, et al. A follow-up
study of outcomes of the Tiwi Renal Treatment
Program. Darwin: NTUniprint, Northern Territory
University, 2003. ❏
Mutual obligation and 
Indigenous health: thinking 
through incentives and 
obligations
John N Burry
TO THE EDITOR: As I have said elsewhere,
“The last thing the majority wants is that the
tyranny of the majority be applied to it. It is
much easier to apply the tyranny of the
majority to a minority. In a properly func-
tioning democratic society minorities are not
subjected to, but are protected against, the
tyranny of the majority. Is the tyranny of the
majority being applied through the medium
of the Howard government onto the Aborig-
inal communities of Australia in this matter
of ‘shared responsibility agreements’?”1
I note with interest recent articles by
Collard and colleagues2 and by Kowal,3
debating “shared responsibility agreements”.
The expressions “shared responsibility
agreement”3 and “mutual obligation” are
variations of the expression “social con-
tract”. The concept of “social contract”
underlies the concept of democracy origi-
nating in the writings of Thomas Hobbes,
John Locke and Jean-Jacques Rousseau.
Present-day political scientists discuss
social-contract theory in their writings about
democracy, and may mention “mutual obli-
gation” or “shared responsibility”. While it is
commonplace for aspects of the social con-
tract to apply to subgroups in the pop-
ulation, it is discriminatory to make
arrangements that apply only to a particular
racial or ethnic group.
Even though the agreements are declared
to be voluntary, it is likely that Aboriginal
communities are under pressure to do as
they are told to achieve social contracts with
the Australian Government. If Indigenous
people must comply with certain conditions
before they can achieve social contracts,
how might similar conditions be applied to
the rest of the Australian population? The
“ticking time bombs” of Australian public
Blood pressure measurements (mm Hg) over 3 years of follow-up after 
enrolment in 123 people who had observations at every interval4
Baseline 6 months 1 year 2 years 3 years
Mean systolic BP (SD) 136.2 (21.6) 125.4 (21.6) 123.6 (20.3) 120.6 (21.6) 121.7 (21.5)
Mean diastolic BP (SD) 81.9 (13.2) 75.5 (13.7) 76.3 (12.9) 74.5 (13.7) 74.0 (11.0)MJA • Volume 185 Number 3 • 7 August 2006 181
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Indigenous Australians refuse to stop smok-
ing and refuse to eat less and take more
exercise, should access to public hospitals
and pharmaceutical benefits be denied
them? Should they be denied petrol to force
them to walk and to use public transport?
Obviously not. These services are not sub-
ject to social-contract agreements as this-
would be a clear violation of Australian law.
Australian members of parliament in par-
ticular, and Australians in general, for the
sake of themselves, their families and of
Australian health care costs, would benefit
from negotiating “shared responsibility
agreements” with themselves to stop smok-
ing and to lose weight. In current circum-
stances, “shared responsibility agreements”
with Aboriginal communities represent
inequality of sharing the responsibility for
health.
John N Burry, Retired Dermatologist
PO Box 2251, Normanville, SA.
burlep@ozemail.com.au
1 Burry JN. Inequality of sharing the responsibility for
health. The Independent Weekly 2005; April: 24-30.
2 Collard KS, D’Antoine HA, Eggington DG, et al.
“Mutual” obligation in Indigenous health: can
shared responsibility agreements be truly mutual?
Med J Aust 2005; 182: 502-504. 
3 Kowal E. Mutual obligation and Indigenous health:
thinking through incentives and obligations. Med J
Aust 2006; 184: 292–293. ❏
More doctors, but not enough: 
Australian medical workforce 
supply 2001–2012
Peter C Arnold
TO THE EDITOR: Where is the evidence
for the claim by Joyce, McNeil and
Stoelwinder1 that there was a boom in med-
ical workforce supply in the 1970s?
They are perpetuating the accepted
macroeconomic myth of there having been a
surplus at that time. The microeconomic,
marketplace truth was that there was a
shortage of general practitioners throughout
the 1970s.2 This was so severe that, after
battling for some years after 1974 to find a
partner for my suburban Sydney practice, I
resorted to advertising overseas, finally
importing an overseas-trained graduate.
It is time for this myth to be laid to rest.
There has been a marketplace shortage of
GPs since the early 1970s.
The truth is that federal governments
have baulked at the expansion of payments
through Medibank/Medicare. Rather than
apply any controls on demand, they have
obstinately rationed supply, repeatedly cit-
ing dubious statistics and invalid interna-
tional comparisons to justify a diminution in
the supply of GPs.
Peter C Arnold, Retired GP
Sydney, NSW.
peter@arnold.name
1 Joyce CM, McNeil JJ, Stoelwinder JU. More doc-
tors, but not enough: Australian medical workforce
supply 2001–2012. Med J Aust 2006; 184: 441-446. 
2 Arnold PC. The ageing GP. Quadrant 1977; XXI: 8-
9. ❏
Catherine M Joyce, John J McNeil and 
Johannes U Stoelwinder
IN REPLY: Our reference to a boom in
medical workforce supply during the 1970s
was based on the marked increase in medi-
cal workforce entries in that decade. The
number of Australian medical graduates
rose from 851 in 1970 to 1278 in 1980.1,2
In contrast — and as a result of a shift to a
policy of constraint — graduate numbers
remained quite static during the 1980s and
1990s, at around 1200–1300 per year
(Commonwealth Department of Education,
Science and Training custom datasets RFI
03-312, RFI 04-360, 2004).
Although the policy shift in the 1980s was
based on a perception of surplus, judge-
ments about workforce adequacy were con-
tentious at that time and remain so. We did
not intend to imply necessarily that there
was a surplus in the medical workforce (or
the general practice workforce specifically)
during the 1970s. Rather, our historical
reference was intended to show the parallels
with the large influx that will result from
current expansion in medical school intakes,
and to highlight the cyclic nature of both
medical workforce policy and perceptions of
adequacy. We agree with Arnold’s implica-
tion that policies which attempt simply to
adjust gross supply (up or down) are insuffi-
cient to ensure an adequate medical work-
force.
Catherine M Joyce, Senior Lecturer
John J McNeil, Professor and Head
Johannes U Stoelwinder, Professor
Department of Epidemiology and Preventive 
Medicine, Monash University, Melbourne, VIC.
catherine.joyce@med.monash.edu.au
1 Karmel P (Chairman). Report of the Committee on
Medical Schools to the Australian Universities Com-
mission. Expansion of medical education. (Parlia-
mentary Paper No. 110.) Canberra: AGPS, 1973.
2 Doherty RL (Chairman). Committee of Inquiry into
Medical Education and the Medical Workforce.
Australian medical education and workforce into
the 21st century. Canberra: AGPS, 1988. ❏
Do women in rural and remote 
areas need different guidelines 
for management of low-grade 
abnormalities found on cervical 
screening?
Stewart Bryant
TO THE EDITOR: We read with interest
the letter by Breeze et al on management of
abnormalities detected on cervical screen-
ing.1 Their study identifies a universal and
fundamental feature of the Pap smear —
namely, that it is an imperfect predictor of
underlying abnormalities in the cervical epi-
thelium.
For smears reported as a low-grade squa-
mous intraepithelial lesion (LSIL) (atypical
squamous cells of uncertain significance) or
possible LSIL, Breeze and colleagues have
shown that underestimation of the extent of
the underlying abnormality is greater in
infrequently screened women than in fre-
quently screened women. They claim that
following the latest National Health and
Medical Research Council (NHMRC) guide-
lines for cervical screening2 will put women
in rural and remote areas with cytologically
detected low-grade lesions at risk of devel-
oping high-grade lesions that go undetected
through lack of timely follow-up. I contend
that following the new NHMRC guidelines
presents a significant risk to all women with
LSIL or possible LSIL reported on smears,
regardless of ethnicity, locality or social
class. The risk is merely greater for women
living in rural and remote areas.
In addition to delays in diagnosis of high-
grade lesions, data from cervical cytology
registries indicate that there will be delays in
diagnosis for the 30–50 women each year
whose smears show changes only of LSIL or
possible LSIL but who are shown on biopsy
to have cervical cancer.3
The problem of women defaulting on
clinic appointments or being lost to follow-
up is a phenomenon commonly encoun-
tered in cervical screening programs in gen-
eral, but in Far North Queensland the risks
of inadequate follow-up are magnified.
For these and other reasons, the Royal
College of Pathologists of Australasia, other
learned societies and individuals have con-
sistently and strenuously opposed the latest
NHMRC guidelines during the period of
their development and during the consulta-
tion period of many months.
Rather than advocate a separate set of
guidelines for women in rural and remote
areas, it would be better to have a univer-182 MJA • Volume 185 Number 3 • 7 August 2006
LETTERSsally accepted safe set of guidelines that
conforms to international best practice and
applies to all Australian women. Using the
guidelines that were in use until 20054 and
that have served us so well in the past is one
option. Another option, which is backed by
first class scientific evidence,5 is to use
human papillomavirus DNA testing for
triage of women with smears reported as
possible LSIL.
Stewart Bryant, President
Royal College of Pathologists of Australasia, 
Sydney, NSW.
bronwyns@rcpa.edu.au
1 Breeze C, de Costa CM, Jagusch M. Do women in
rural and remote areas need different guidelines for
management of low-grade abnormalities found on
cervical screening? Med J Aust 2006; 184: 307-308. 
2 National Health and Medical Research Council.
Screening to prevent cervical cancer: guidelines for
the management of asymptomatic women with
screen detected abnormalities. Canberra: Com-
mo n we a lt h  o f  A u s t ra l ia ,  2 0 05 .  h t t p : / /
www.nhmrc.gov.au/publications/_files/wh39.pdf
(accessed Jul 2006).
3 Mitchell H. Outcome after a cervical cytology report
of low-grade squamous abnormality in Australia.
Cancer 2005; 105: 185-193.
4 National Health and Medical Research Council.
Screening to prevent cervical cancer: guidelines for
management of asymptomatic women with screen
detected abnormalities. Canberra: Commonwealth
of Australia, 1994. http://www.csp.nsw.gov.au/
downloads/wh16.pdf (accessed Jul 2006).
5 Schiffman M, Solomon D. Findings to date from the
ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab
Med 2003; 127: 946-949. ❏
Gerard V Wain, Ian G Hammond, 
Penelope I Blomfield, Marion A Saville 
and Margaret Davy, on behalf of the 
Guidelines Review Group
IN REPLY: In June 2005, the National
Health and Medical Research Council
(NHMRC) endorsed new guidelines for
managing asymptomatic women with
screen-detected abnormalities because they
were safe for Australian women and were
based on the best available Australian and
international evidence.1 The NHMRC
accepted that new information about the
natural history of human papillomavirus
(HPV) infection of the cervix and cervical
neoplasia demanded a reassessment of our
traditional approach to this disease.
HPV infection of the cervix and associ-
ated, potentially neoplastic precursor lesions
are very common, but not all of these have
malignant potential. Optimal prevention of
cervical cancer will depend on timely diag-
nosis and treatment of lesions that are most
likely to progress. Overdiagnosis and treat-
ment of all incident lesions is unnecessary
and potentially results in avoidable morbid-
ity. The approach recommended in the latest
guidelines moves away from probabilistic
prediction and intensive investigation based
on a single cytological specimen to an evi-
dence-based program of intermittent cyto-
logical surveillance of this chronic viral
infection. Intervention is timed to coincide
with evidence of persistent and potentially
dangerous infection.
Contrary to Bryant’s claim about Austral-
ian registry data, there is no evidence that
the new guidelines will mean any increase in
the diagnosis of cancer, a view that is sup-
ported by independent epidemiological
expert review (M Clements, Research Fel-
low, National Centre for Epidemiology and
Population Health, Australian National Uni-
versity, personal communication). The
experience of Breeze and colleagues in Far
North Queensland suggests that the greatest
risk factor for any woman to develop cervi-
cal cancer is infrequent screening.2 Further-
more, in the unlikely event that the latest
guidelines do result in increased cancer
incidence, such an increase will immediately
be detected by the monitoring program that
is integral to the new approach.
Bryant advocates increased pathology
testing using HPV DNA tests. We are not
aware of any population data demonstrating
that such an approach would result in
improved cancer prevention, nor that such
an approach would be cost-effective. Conse-
quently, the Guidelines Review Group did
not recommend the use of HPV DNA testing
as part of triage of women with abnormal
smears. The approach recommended in the
guidelines is also consistent with contempo-
rary international experience3 — namely,
that the clinical significance of a single
incident measurement of HPV status is not
established.
We believe that the latest NHMRC
guidelines1 are safe and acceptable for all
Australian women and that all women
deserve appropriate investigation and treat-
ment of cervical abnormalities in a manner
that will protect them from both cervical
cancer and unnecessary, potentially harmful
interventions.
Finally, to address the concerns of Breeze
and colleagues, the guidelines specifically
advise that clinical management be tailored
to the patient’s individual circumstances.
Gerard V Wain, Director1
Ian G Hammond, Professor2
Penelope I Blomfield, Director3
Marion A Saville, Director4
Margaret Davy, Director5
1 Gynaecological Oncology, Westmead 
Hospital, Sydney, NSW.
2 Gynaecological Oncology, King Edward 
Memorial Hospital, Perth, WA.
3 Gynaecological Oncology, Royal Hobart 
Hospital, Hobart, TAS.
4 Victorian Cytology Service, Melbourne, VIC.
5 Gynaecological Oncology, Royal Adelaide 
Hospital, Adelaide, SA.
gerard_wain@wsahs.nsw.gov.au
1 National Health and Medical Research Council.
Screening to prevent cervical cancer: guidelines for
the management of asymptomatic women with
screen detected abnormalities. Canberra: Com-
mo n we a l th  o f  A u s t r al i a ,  2 0 0 5.  h t tp : / /
www.nhmrc.gov.au/publications/_files/wh39.pdf
(accessed Jul 2006).
2 Breeze C, de Costa CM, Jagusch M. Do women in
rural and remote areas need different guidelines for
management of low-grade abnormalities found on
cervical screening? Med J Aust 2006; 184: 307-308. 
3 Bentley E, Cotton SC, Cruickshank ME, et al. Refin-
ing the management of low-grade cervical abnor-
malities in the UK National Health Service and
defining the potential for human papillomavirus
testing: a commentary on emerging evidence. J
Low Genit Tract Dis 2006; 10: 26-38. ❏
The success and unrealised 
potential of the National 
Cancer Control Initiative
J Mark Elwood, Robert C Burton and 
Michael A Quinn
TO THE EDITOR: The National Cancer
Control Initiative (NCCI) was established in
1997 jointly by the Department of Health
and Ageing and The Cancer Council Aus-
tralia to “provide timely advice, identify
appropriate initiatives, and make specific
recommendations to the Commonwealth
Government and other key groups regarding
the prevention, detection, treatment and
palliation of cancer for all Australians”. It
has been the only independent group deal-
ing with all aspects of cancer nationally, and
incorporating government, non-govern-
ment, consumer and professional input.
On 31 May 2006, it ceased operation due
to lack of funding support, and no arrange-
ments have been made to allow continuity
between its work and that of a proposed
new body, Cancer Australia, which at the
time of writing was still not functioning.
The NCCI’s contributions include
national surveys of colorectal cancer man-
agement and of skin cancer incidence and
treatment; clinical trials assessing the man-
agement of skin lesions in primary care; the
first protocols for pilot programs for bowel
cancer screening; national programs to pro-
mote the implementation of National HealthMJA • Volume 185 Number 3 • 7 August 2006 183
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and Medical Research Council guidelines on
psychosocial aspects of cancer and on lung
and other cancers; programs to improve
decision making in prostate cancer screen-
ing; a nationally agreed core clinical dataset
for cancers; support for cancer registries to
include staging and survival information;
new methods to establish evidence-based
requirements for radiotherapy services; and
support for cancer research, for strengthen-
ing clinical trials and for consumers’ activi-
ties. Since 2000, the small group of NCCI
staff has produced seven national work-
shops, over 30 published reports, and over
60 peer-reviewed articles. These are availa-
ble online at <http://www.ncci.org.au/>
along with current contact details of NCCI
staff, and the final report of the NCCI is at
<http://www.ncci.org.au/pdf/Final%20
report/NCCI_final_report.pdf>.
An independent review in 2004 reported
that NCCI’s work was of high quality, well
researched, insightful, and cost-efficient,
and recommended a considerable increase
in funding. A major contribution of NCCI
was producing, jointly with The Cancer
Council Australia and the Clinical Oncology
Society of Australia, the report Optimising
cancer care in Australia. The government’s
2004 election policy on cancer (http://
www.health.gov.au/internet/budget/publish-
ing .nsf /Content /hea l th-budget2005-
hbudget-hfact1.htm) was based partly on
this report, and included setting up Cancer
Australia, with terms of reference overlap-
ping those of NCCI. The assumption of
many policymakers, consumer representa-
tives and cancer experts was that NCCI
would become a component of Cancer Aus-
tralia. This has not happened. Indeed, from
2005, proposals from NCCI for the planned
next stages of work on topics including
psychosocial aspects of cancer, lung cancer,
and primary care in cancer, received no
response from the Department of Health
and Ageing.
With the closure of NCCI, the Director
and Deputy Director are relocating overseas,
and the highly productive staff members,
specifically praised in the independent
review, are moving to other roles. The pre-
mature demise of the NCCI, before Cancer
Australia has started to function, is short-
sighted, inefficient, and wastes the experi-
ence, resources and staff that NCCI has
developed. This finishes a decade-long
unique partnership between the Australian
Government and non-government national
cancer organisations. Cancer Australia will
need to develop anew the expertise to iden-
tify and address issues in cancer control in
Australia, and to link the government and
non-government sectors.
J Mark Elwood, Director
Robert C Burton, Chair, National Cancer 
Strategies Group, and Past Chair, Management 
Committee
Michael A Quinn, Chair, Management 
Committee
National Cancer Control Initiative, Melbourne, 
VIC.
mark.elwood@cancervic.org.au ❏
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